Immune-mediated chronic inflammatory diseases, new Biogen biosimilar formulation for a more comfortable injection procedure

2023-05-09 18:52:40

Biogen has announced the availability in Italy of the new low-volume, citrate-free formulation of its biosimilar drug adalimumab, indicated in the European Union for the treatment of immune-mediated chronic inflammatory diseases that affect over 2 million people in Italy. The more comfortable injection procedure offered by the drug promotes greater patient compliance